Navigation Links
CVS Caremark Reports Strong First Quarter Results
Date:5/1/2013

WOONSOCKET, R.I., May 1, 2013 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO )

First Quarter Year-over-year Highlights:

  • Operating profit increased 21.0% to $1.7 billion
  • Adjusted EPS increased 28.1% to $0.83; GAAP diluted EPS from continuing operations increased 29.9% to $0.77
  • Retail pharmacy same store prescription volumes increased 2.0%; 4.7% on a 30-day equivalent basis
  • Retail pharmacy same store sales declined 2.3% due to new generic introductions; front store same store sales increased 1.4%
  • Generated free cash flow of $1.3 billion; cash flow from operations of $1.6 billion
  • 2013 Guidance:

  • Narrowed 2013 full year Adjusted EPS range to $3.89 to $4.00 and GAAP diluted EPS from continuing operations range narrowed to $3.64 to $3.75
  • Provided second quarter Adjusted EPS guidance of $0.94 to $0.97 and GAAP diluted EPS from continuing operations guidance of $0.88 to $0.91
  • Reconfirmed full year free cash flow of $4.8 to $5.1 billion and cash flow from operations of $6.4 to $6.6 billion
  • RevenuesNet revenues for the three months ended March 31, 2013, decreased 0.1%, or $35 million, compared to the three months ended March 31, 2012.

    Revenues in the Pharmacy Services Segment increased 0.1% in the three months ended March 31, 2013. The growth was primarily driven by volume increases across all channels and drug cost inflation in our specialty pharmacy business, mostly offset by the impact of new generic introductions. When substituted for brand equivalents, generic drugs lower revenue while increasing profit. Pharmacy network claims processed during the three months ended March 31, 2013, increased 4.3% to 207.1 million, compared to 198.5 million in the prior year period. The increase in pharmacy network claims was primarily due to higher claims activity associated with 1) new clients, 2) a strong flu season and 3) our Medicare Part D program. Mail choice claims processed during the three months ended March 31, 2013, increased approximately 0.6% to 20.5 million, compared to 20.4 million in the prior year period. The increase in the mail choice claim volume was primarily due to increased claims associated with the continuing adoption of our Maintenance Choice offerings.

    Revenues in the Retail Pharmacy Segment increased 0.2% in the three months ended March 31, 2013. Same store sales decreased 1.2% when compared to the prior year period, with pharmacy same store sales down 2.3% and front store same store sales up 1.4%. The change in same store sales was primarily driven by new generic drug introductions, a strong flu season, the shift of the Easter holiday from April in 2012 to March in 2013 and the absence of leap day in 2013. Pharmacy same store prescription volumes rose 2.0% when 90-day prescriptions are counted as one prescription. On a 30-day equivalent basis, same store prescription volumes increased 4.7% in the quarter. Pharmacy same store sales were negatively impacted by approximately 925 basis points due to recent generic introductions. The high incidence of flu positively impacted pharmacy same store sales by approximately 90 basis points. Front store same store sales were positively impacted by 65 basis points due to the earlier Easter holiday. The absence of leap day in the three months ended March 31, 2013, had a negative impact on pharmacy same store sales of approximately 70 basis points and front store same store sales of approximately 120 basis points.

    The increases in revenue in the Pharmacy Services and Retail Pharmacy segments were offset by an increase in intersegment activity primarily driven by the continued adoption of our Maintenance Choice program.

    For the three months ended March 31, 2013, the generic dispensing rate increased approximately 400 basis points in our Pharmacy Services Segment, to 80.5%, and approximately 300 basis points in our Retail Pharmacy Segment, to 81.2%, compared to the prior year period.

    Income from Continuing Operations Attributable to CVS CaremarkIncome from continuing operations attributable to CVS Caremark for the three months ended March 31, 2013, increased 23.1%, or $179 million, to $956 million, compared with $777 million during the three months ended March 31, 2012. The increase in income from continuing operations was primarily driven by the positive impact from new generics, which significantly improved operating profit in both our Pharmacy Services and Retail Pharmacy segments. Adjusted earnings per share from continuing operations attributable to CVS Caremark (Adjusted EPS) for the three months ended March 31, 2013 and 2012, was $0.83 and $0.65, respectively, an increase of 28.1%. Adjusted EPS excludes $122 million and $118 million of intangible asset amortization related to acquisition activity in the three months ended March 31, 2013 and 2012, respectively. GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for the three months ended March 31, 2013 and 2012, was $0.77 and $0.59, respectively.

    President and Chief Executive Officer Larry Merlo, said, "I'm very pleased with our strong first quarter results. As expected, the  influx of new generic drugs was a key driver across the enterprise, resulting in solid gross margin expansion as well as significant growth in operating profit and earnings. In fact, operating profit grew well beyond our expectations across the enterprise, and we delivered EPS that was three cents above the high end of our guidance. This out-performance was driven by stronger-than-expected prescription volumes due in large part to the strong flu season, strong specialty growth, and favorable purchasing and rebate economics."

    Mr. Merlo continued, "Furthermore, we generated a substantial amount of free cash this quarter. We remain committed to our disciplined capital allocation strategy, which is enabling us to return significant value to our shareholders through both dividends and share repurchases."

    Real Estate ProgramDuring the three months ended March 31, 2013, the Company opened 37 new retail drugstores and closed nine retail drugstores. In addition, the Company relocated 15 retail drugstores. As of March 31, 2013, the Company operated 7,596 locations in 45 states, the District of Columbia, Puerto Rico and Brazil. These locations included 7,531 retail drugstores, 18 onsite pharmacies, 31 retail specialty pharmacy stores, 12 specialty mail order pharmacies and four mail order pharmacies.

    GuidanceThe Company narrowed its earnings guidance range for the full year 2013 to reflect the solid first quarter performance to date and the outlook for the remainder of the year. The Company currently expects to deliver Adjusted EPS of $3.89 to $4.00 and GAAP diluted earnings per share from continuing operations of $3.64 to $3.75 per share in 2013. The guidance includes the estimated impact on our Medicare Part D business from sequestration. It also includes costs in our Medicare Part D business associated with resolving issues that arose following plan consolidation at the beginning of the year. The Company reconfirmed its 2013 free cash flow guidance of $4.8 billion to $5.1 billion, and its 2013 cash flow from operations guidance of $6.4 billion to $6.6 billion. These 2013 guidance estimates assume the completion of $4.0 billion in share repurchases.

    Teleconference and WebcastThe Company will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss its quarterly results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com/investors. This webcast will be archived and available on the website for a one-year period following the conference call.

    About the CompanyCVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the Company's more than 7,400 CVS/pharmacy® stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 600 MinuteClinic® locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans. As a pharmacy innovation company with an unmatched breath of capabilities, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor® program that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about how CVS Caremark is reinventing pharmacy for better health at http://info.cvscaremark.com/.

    Forward-Looking StatementsThis press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.

     — Tables Follow —

      

    CVS CAREMARK CORPORATIONCondensed Consolidated Statements of Income(Unaudited) Three Months EndedMarch 31,In millions, except per share amounts20132012Net revenues$

    30,763$

    30,798Cost of revenues25,18125,685Gross profit5,5825,113Operating expenses3,8833,709Operating profit1,6991,404Interest expense, net126132Income before income tax provision1,5731,272Income tax provision617496Income from continuing operations956776Loss from discontinued operations, net of tax—(1)Net income956775Net loss attributable to noncontrolling interest—1Net income attributable to CVS Caremark$

    956$

    776Income from continuing operations attributable to CVS Caremark:Income from continuing operations$

    956$

    776Net loss attributable to noncontrolling interest—1Income from continuing operations attributable to CVS Caremark$

    956$

    777Basic earnings per common share:Income from continuing operations attributable to CVS Caremark$

    0.78$

    0.60Loss from discontinued operations attributable to CVS Caremark——Net income attributable to CVS Caremark$

    0.78$

    0.60Weighted average basic common shares outstanding1,2321,299Diluted earnings per common share:Income from continuing operations attributable to CVS Caremark$

    0.77$

    0.59Loss from discontinued operations attributable to CVS Caremark——Net income attributable to CVS Caremark$

    0.77$

    0.59Weighted average diluted common shares outstanding1,2411,309Dividends declared per common share$

    0.2250$

    0.1625 

     

    CVS CAREMARK CORPORATIONCondensed Consolidated Balance Sheets(Unaudited) March 31,December 31,In millions, except per share amounts20132012Assets:Cash and cash equivalents$

    1,551$

    1,375Short-term investments55Accounts receivable, net6,6356,473Inventories10,59210,759Deferred income taxes604663Other current assets340577Total current assets19,72719,852Property and equipment, net8,5568,632Goodwill26,57526,395Intangible assets, net9,7389,753Other assets1,4721,280Total assets$

    66,068$

    65,912Liabilities:Accounts payable$

    5,506$

    5,070Claims and discounts payable3,8543,974Accrued expenses3,5234,051Short-term debt300690Current portion of long-term debt125Total current liabilities13,19513,790Long-term debt9,3529,133Deferred income taxes3,7743,784Other long-term liabilities1,5381,501Commitments and contingenciesShareholders' equity:Preferred stock, par value $0.01: 0.1 shares authorized;

      none issued or outstanding——Common stock, par value $0.01: 3,200 shares authorized; ,671 shares issued and 1,228 shares outstanding at March 31, 2013 and 1,667 shares issued and 1,231 shares outstanding at December 31, 201217 

    17Treasury stock, at cost: 441 shares at March 31, 2013 and

      435 shares at December 31, 2012(16,625)(16,270)Shares held in trust: 1 share at March 31, 2013 and 

      December 31, 2012(31)(31)Capital surplus29,30229,120Retained earnings25,72825,049Accumulated other comprehensive loss(182)(181)Total shareholders' equity38,20937,704Total liabilities and shareholders' equity$

    66,068$

    65,912 

     

     

    CVS CAREMARK CORPORATIONCondensed Consolidated Statements of Cash Flows(Unaudited) Three Months EndedMarch 31,In millions20132012Cash flows from operating activities:Cash receipts from customers$

    28,018$

    29,207Cash paid for inventory and prescriptions dispensed by retail

      network pharmacies(22,270)(22,515)Cash paid to other suppliers and employees(3,889)(3,751)Interest received11Interest paid(104)(128)Income taxes paid(116)(28)Net cash provided by operating activities1,6402,786Cash flows from investing activities:Purchases of property and equipment(318)(376)Proceeds from sale of property and equipment5—Acquisitions (net of cash acquired) and other investments(254)(74)Proceeds from sale of subsidiary—7Net cash used in investing activities(567)(443)Cash flows from financing activities:Decrease in short-term debt(390)(750)Repayments of long-term debt—(52)Dividends paid(277)(211)Proceeds from exercise of stock options150278Excess tax benefits from stock-based compensation13—Repurchase of common stock(393)(810)Net cash used in financing activities(897)(1,545)Net increase in cash and cash equivalents176798Cash and cash equivalents at the beginning of the year1,3751,413Cash and cash equivalents at the end of the year$

    1,551$

    2,211Reconciliation of net income to net cash provided by operating

     activities:Net income$

    956$

    775Adjustments required to reconcile net income to net cash

     provided by operating activities:Depreciation and amortization502423Stock-based compensation3436Deferred income taxes and other non-cash items6621Change in operating assets and liabilities, net of effects 

      of acquisitions:Accounts receivable, net(113)(70)Inventories193(776)Other current assets238286Other assets(135)(189)Accounts payable and claims and discounts payable(230)1,044Accrued expenses1051,250)Other long-term liabilities24(14)Net cash provided by operating activities$

    1,640$

    2,786 

    Adjusted Earnings Per Share 
    (Unaudited)For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.

    The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, plus net loss attributable to noncontrolling interest divided by the weighted average diluted common shares outstanding.

    The following is a reconciliation of income before income tax provision to adjusted earnings per share: 

     Three Months EndedMarch 31,In millions, except per share amounts20132012Income before income tax provision$

    1,573$

    1,272Amortization122118Adjusted income before income tax provision1,6951,390Adjusted income tax provision(1) 664542Adjusted income from continuing operations1,031848Net loss attributable to noncontrolling interest—1Adjusted income from continuing operations attributable to CVS Caremark$

    1,031$

    849Weighted average diluted common shares outstanding1,2411,309Adjusted earnings per share from continuing operations attributable to CVS Caremark$

    0.83$

    0.65 

    (1)
    The adjusted income tax provision is computed using the effective income tax rate from the consolidated statements of income. 

    Free Cash Flow 
    (Unaudited)The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).

    The following is a reconciliation of net cash provided by operating activities to free cash flow:Three Months EndedMarch 31,In millions20132012Net cash provided by operating activities$

    1,640$

    2,786Subtract: Additions to property and equipment(318)(376)Free cash flow$

    1,322$

    2,410 

    Supplemental Information 
    (Unaudited)The Company evaluates its Pharmacy Services and Retail Pharmacy Segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:

    In millionsPharmacy ServicesSegment(1)Retail Pharmacy SegmentCorporate SegmentIntersegment Eliminations(2)ConsolidatedTotalsThree Months EndedMarch 31, 2013:Net revenues$

    18,311$

    16,051$

    —$

    (3,599)$

    30,763Gross profit7684,952—(138)5,582Operating profit (loss)4991,537(199)(138)1,699March 31, 2012Net revenues18,30016,024—(3,526)30,798Gross profit6164,572—(75)5,113Operating profit (loss)3491,298(168)(75)1,404 

    (1)
    Net revenues of the Pharmacy Services Segment include approximately $2.2 billion and $2.3 billion of retail co-payments for the three months ended March 31, 2013 and 2012, respectively.(2)
    Intersegment eliminations relate to two types of transaction: (i) Intersegment revenues that occur when Pharmacy Services Segment customers use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment customers, through the Company's intersegment activities (such as the Maintenance Choice program), elect to pick-up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $939 million and $798 million for the three months ended March 31, 2013 and 2012, respectively, gross profit and operating profit of $138 million and $75 million for the three months ended March 31, 2013 and 2012, respectively. 

    Supplemental Information 
    (Unaudited)Pharmacy Services SegmentThe following table summarizes the Pharmacy Services Segment's performance for the respective periods:Three Months EndedMarch 31,In millions20132012Net revenues$

    18,311$

    18,300Gross profit768616Gross profit % of net revenues4.2%3.4%Operating expenses269267Operating expense % of net revenues1.5%1.5%Operating profit499349Operating profit % of net revenues2.7%1.9%Net revenues(1):Mail choice(2)$

    5,869$

    5,666Pharmacy network(3)12,39212,584Other5050Pharmacy claims processed(1):Total227.6218.9Mail choice(2)20.520.4Pharmacy network(3)207.1198.5Generic dispensing rate(1):Total80.5%76.5%Mail choice(2)75.4%69.0%Pharmacy network(3)81.0%77.3%Mail choice penetration rate22.1%22.8% 

    (1)
    Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category.(2)
    Mail choice is defined as claims filled at a Pharmacy Services' mail facility, which include specialty mail claims, as well as 90-day claims filled at retail under the Maintenance Choice program.(3)
    Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity. 

    Supplemental Information 
    (Unaudited)Retail Pharmacy SegmentThe following table summarizes the Retail Pharmacy Segment's performance for the respective periods:Three Months Ended March 31,In millions20132012Net revenues$

    16,051$

    16,024Gross profit4,9524,572Gross profit % of net revenues30.9%28.5%Operating expenses3,4153,275Operating expense % of net revenues21.3%20.4%Operating profit1,5371,298Operating profit % of net revenues9.6%8.1%Retail prescriptions filled (90 Day = 1Rx)184.7179.5Retail prescriptions filled (90 Day = 3 Rx) (1)221.5210.0Net revenue increase:Total0.2%9.9%Pharmacy(1.1)%11.1%Front store3.1%7.1%Total prescription volume (90 Day = 1 Rx)2.9%8.4%Total prescription volume (90 Day = 3 Rx) (1)5.5%10.4%Same store increase (decrease):Total sales(1.2)%8.4%Pharmacy sales(2.3)%9.8%Front store sales1.4%5.3%Prescription volume (90 Day = 1 Rx)2.0%7.2%Prescription volume (90 Day = 3 Rx) (1)4.7%9.2%Generic dispensing rate81.2%78.1%Pharmacy % of total revenues69.0%69.9%Third party % of pharmacy revenue97.8%97.7% 

    (1)
    Includes the adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. 

    Adjusted Earnings Per Share Guidance 
    (Unaudited)The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.

     

    In millions, except per share amountsYear EndingDecember 31, 2013Income before income tax provision$

    7,257$

    7,435Amortization495495Adjusted income before income tax provision7,7527,930Adjusted income tax provision3,0073,076Adjusted income from continuing operations4,7454,854Net loss attributable to noncontrolling interest——Adjusted income from continuing operations attributable to CVS Caremark$

    4,745$

    4,854Weighted average diluted common shares outstanding1,2211,215Adjusted earnings per share from continuing operations attributable to CVS Caremark$

    3.89$

    4.00 

     Three Months EndingJune 30, 2013Income before income tax provision$

    1,780$

    1,843Amortization123124Adjusted income before income tax provision1,9031,967Adjusted income tax provision746771Adjusted income from continuing operations1,1571,196Net loss attributable to noncontrolling interest——Adjusted income from continuing operations attributable to CVS Caremark$

    1,157$

    1,196Weighted average diluted common shares outstanding1,2291,227Adjusted earnings per share from continuing operations attributable to CVS Caremark$

    0.94$

    0.97 

    Free Cash Flow Guidance 
    (Unaudited)The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-to-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.

     

    In millionsYear EndingDecember 31, 2013Net cash provided by operating activities$

    6,350$

    6,550Subtract: Additions to property and equipment(2,200)(2,000)Add: Proceeds from sale-leaseback transactions600500Free cash flow$

    4,750$

    5,050 


    '/>"/>
    SOURCE CVS Caremark Corporation
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. CVS Caremark Offers Advice on Proper Management, Storage and Disposal of Medications in Light of New Study on Teen Abuse of Prescription Drugs
    2. Cardinal Health Will Continue To Supply Pharmaceuticals To CVS Caremark Corporation
    3. CVS Caremark Industry-Leading Generic Dispensing Rate Reduces Client Traditional Drug Spend by 3.6 Percent for 2012
    4. CVS Caremark Charitable Trust Supports Non-profits Nationwide with $2.6 Million in Funding
    5. CVS Caremark Research Finds Medication Adherence Can Improve Outcomes and Reduce Costs for Patients with Coronary Artery Disease
    6. CVS Caremark MinuteClinic President Discusses Primary Care Innovation at London Healthcare Conferences
    7. CVS Caremark Emphasizes Commitment to Older Americans at Annual American Society on Aging Conference
    8. Accordant Health Services, a CVS Caremark Company, Receives URAC Case Management Accreditation
    9. CVS Caremark CEO Addresses Economic Club of Pittsburgh on Reinventing Pharmacy for Better Health
    10. CVS Caremark Appoints New Chief Digital Officer to Lead Digital Innovation Team
    11. CVS Caremark Encourages Heart Healthy Behavior During American Heart Month
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... Calif. , Feb. 11, 2016 ... the use of the iFuse Implant System, a ... for certain disorders of the sacroiliac (SI) joint, ... the cost benefits of MIS SI joint fusion ... due to degenerative sacroiliitis or SI joint disruption.  ...
    (Date:2/11/2016)...  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) announced today ... 25 at 11:30 a.m. Eastern Time to discuss its 2015 ... www.ionispharma.com . A webcast replay will be available ... www.ionispharma.com . A webcast replay will be available for ... Interested parties may listen to the call by dialing 877-443-5662 ...
    (Date:2/11/2016)... Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... the development of a once-daily, oral therapy for the ... Medical Officer, Dr. Maya Halpern , has notified the ... Medical Officer and from its Board of Directors effective ... retirement age. Allen Baharaff . Mr. Baharaff ...
    Breaking Medicine Technology:
    (Date:2/11/2016)... ... , ... The book, “Computers Should Just Work!”, provides a basic, non-techie education ... consultant before signing a contract and how to spot an incompetent or dishonest IT ... on e-mail and technology, it’s more important than ever to make sure the company ...
    (Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting of ... (WMIC), will be held in New York City, NY on September 7 – ... congress will highlight and emphasize how imaging reveals a greater understanding of the ...
    (Date:2/10/2016)... ... February 10, 2016 , ... ... full-service health care communications company offering education, research and medical media, has ... and specialists working in infectious diseases. , As the all-inclusive resource for ...
    (Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
    (Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Emergency rooms ... harder to find. Unfortunately, this can leave patients with dental emergencies at risk of ... is now offering emergency dental care. , Common dental emergencies include:, ...
    Breaking Medicine News(10 mins):